CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.040
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
2.040
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:03 AM EST

CytomX Therapeutics Stock Forecast

CTMX's stock price has decreased by -51.77% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 8 analysts polled by S&P Global, CytomX Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.38. The average 1-year stock price forecast is 506.86% higher than the current stock price, while the lowest is $5.00 (+145.10%) and the highest is $16 (+684.31%).

Price Target: $12.38 (+506.86%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$5.00$12.38$12$16
Change+145.10%+506.86%+488.24%+684.31%

Analyst Ratings

The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Aug '26Sep '26Oct '26Nov '26
Strong Buy655555
Buy333333
Hold000000
Sell000000
Strong Sell000000
Total988888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Buy
Maintains
$11 → $12
BuyMaintains$11 → $12+488.24%Nov 12, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$12
BuyMaintains$12+488.24%Nov 6, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$12
BuyReiterates$12+488.24%Nov 6, 2026
Guggenheim
Guggenheim
Buy
Maintains
$14
BuyMaintains$14+586.27%Nov 6, 2026
Wedbush
Wedbush
Buy
Maintains
$11 → $12
BuyMaintains$11 → $12+488.24%Nov 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
21.96M
from 76.20M
Decreased by -71.19%
Revenue Next Year
29.98M
from 21.96M
Increased by 36.55%
EPS This Year
-0.39
from -0.15
EPS Next Year
-0.50
from -0.39
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
37.31M53.16M101.21M138.10M76.20M21.96M
Revenue Growth
-45.47%42.48%90.38%36.45%-44.82%-71.19%
Gross Profit
37.31M53.16M101.21M138.10M76.20M21.96M
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Income
-116.04M-93.84M-6.48M25.00M-19.56M-87.93M
Net Income
-115.87M-99.32M-569.00K31.87M-17.37M-79.20M
EPS
-----0.15-0.39
Free Cash Flow
-----75.81M-77.00M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High31.3M
Avg22.0M
Low11.9M

Revenue Growth

Revenue Growth202620272028
High
-58.9%
Avg
-71.2%
Low
-84.3%

EPS Forecast

EPS202620272028
High-0.33
Avg-0.39
Low-0.51

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-